Skip to main content

Advertisement

Log in

Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Three adolescents with central nervous system (CNS) negative acute myeloid leukaemia (AML) refused cranial irradiation for CNS prophylaxis. Instead, these patients received four doses of 50 mg of intrathecal (IT) liposomal cytarabine on day 1, 15, 43 and 71 of maintenance therapy. Corticosteroids were given to prevent chemical arachnoiditis. All patients developed bilateral papilloedema after the third or fourth dose of liposomal cytarabine, local side effects were observed in two patients. Under prolonged dexamethasone therapy, side effects resolved completely. As reversible neuroophthalmological side effects caused by intrathecal liposomal cytarabine can also be observed under low-dose maintenance therapy in patients with CNS negative AML, it should be used with caution in children and adolescents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Benesch M, Sovinz P, Krammer B, Lackner H, Mann G, Schwinger W et al (2007) Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis. J Pediatr Hematol Oncol 29:222–226 doi:10.1097/MPH.0b013e318041f112

    Article  PubMed  CAS  Google Scholar 

  2. Bomgaars L, Geyer JR, Franklin J, Dahl G, Park J, Winick NJ et al (2004) Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol 22:3916–3921 doi:10.1200/JCO.2004.01.046

    Article  PubMed  CAS  Google Scholar 

  3. Chamberlain MC, Glantz MJ (2007) Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphatic leukaemia. Blood 110:1698 author reply 1698–1699 doi:10.1182/blood-2007-02-073536

    Article  PubMed  CAS  Google Scholar 

  4. Chamberlain MC, Kormanik P, Howell SB, Kim S (1995) Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol 52:912–917

    PubMed  CAS  Google Scholar 

  5. Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G et al (2005) Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 19:2030–2042 doi:10.1038/sj.leu.2403920

    Article  PubMed  CAS  Google Scholar 

  6. Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T (2004) Early deaths and treatment related mortality in children undergoing therapy for acute myeloid leukaemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 22:4384–4393 doi:10.1200/JCO.2004.01.191

    Article  PubMed  Google Scholar 

  7. Glantz MJ, La Folette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR et al (1999) Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17:3110–3116

    PubMed  CAS  Google Scholar 

  8. Goshen Y, Stark B, Kornreich L, Michowiz S, Feinmesser M, Yaniv I (2007) High incidence of meningioma in cranial irradiated survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 49:294–297 doi:10.1002/pbc.21153

    Article  PubMed  Google Scholar 

  9. Hata M, Ogino I, Aida N, Saito K, Omura M, Kigasawa H et al (2001) Prophylactic cranial irradiation of acute lymphoblastic leukemia in childhood: outcomes of late effects on pituitary function and growth in long-term survivors. Int J Cancer 96(Suppl):117–124 doi:10.1002/ijc.10348

    Article  PubMed  CAS  Google Scholar 

  10. Jabbour E, O’Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F et al (2007) Neurological complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 109:3214–3218 doi:10.1182/blood-2006-08-043646

    Article  PubMed  CAS  Google Scholar 

  11. McClune B, Buadi FK, Aslam N, Przepiorka D (2007) Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukaemia and high-grade lymphoma. Leuk Lymphoma 48:1849–1851 doi:10.1080/10428190701573232

    Article  PubMed  Google Scholar 

  12. Pui C-H (2007) Toward optimal use of intrathecal liposomal cytarabine. Leuk Lymphoma 48:1672–1673 doi:10.1080/10428190701573687

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Constanze Sommer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sommer, C., Lackner, H., Benesch, M. et al. Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia. Ann Hematol 87, 887–890 (2008). https://doi.org/10.1007/s00277-008-0521-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-008-0521-9

Keywords

Navigation